
Primo Biotechnology Secures A Funding and Targets 2026 IPO to Strengthen Global Radiopharmaceutical Strategy
TAIPEI, Taiwan, July 02, 2025 (GLOBE NEWSWIRE) -- Primo Biotechnology Co., Ltd., a pioneering radiopharmaceutical company in Taiwan, announced the successful completion of its NT$220 million Series A funding round. With total capital raised now exceeding …